WHO ICTRP trial
A multicentre phase III randomised double-blind placebo-controlled trial of…
ISRCTN45605573 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN45605573 |
|---|---|
| Public title | A multicentre phase III randomised double-blind placebo-controlled trial of pravastatin added to first-line chemotherapy in patients with non-small cell lung cancer (LungStar 2 trial) |
| Scientific title | A multicentre phase III randomised double-blind placebo-controlled trial of pravastatin added to first-line chemotherapy in patients with non-small cell lung cancer (LungStar 2 trial) |
| Primary sponsor | Imperial College London |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase III |
| Countries | Ireland;United Kingdom |
| Conditions | Stage 3B that is unsuitable for chemoradiation and stage 4 non-small cell lung cancer Cancer Non-small cell lung cancer (NSCLC) |
| Interventions | Patients will receive chemotherapy with docetaxel and either carboplatin or cisplatin. They will be randomised to either pravastatin or placebo. Chemotherapy will last for four cycles unless there is evidence of progression or occurrence of… |
| Registration date | Feb 17, 2006 |
| Target size | 1270 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: